Research Analysts Offer Predictions for SRPT FY2024 Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Investment analysts at William Blair upped their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors on Tuesday, January 21st. William Blair analyst S. Corwin now expects that the biotechnology company will post earnings per share of $2.73 for the year, up from their previous estimate of $2.03. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.39 per share. William Blair also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $1.92 EPS and FY2025 earnings at $11.70 EPS.

A number of other research firms have also issued reports on SRPT. Piper Sandler decreased their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. HC Wainwright reaffirmed a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, January 15th. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Needham & Company LLC reiterated a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, January 14th. Finally, Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They issued a “buy” rating and a $165.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $178.71.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $119.14 on Thursday. The company has a fifty day simple moving average of $121.93 and a two-hundred day simple moving average of $128.71. The company has a market cap of $11.38 billion, a price-to-earnings ratio of 95.31 and a beta of 0.77. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 52 week low of $102.15 and a 52 week high of $173.25.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of large investors have recently made changes to their positions in the stock. Teachers Retirement System of The State of Kentucky purchased a new stake in Sarepta Therapeutics during the second quarter worth $4,771,000. Simplify Asset Management Inc. boosted its position in shares of Sarepta Therapeutics by 84.6% in the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock worth $24,105,000 after buying an additional 88,474 shares in the last quarter. Geode Capital Management LLC grew its stake in Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after acquiring an additional 44,306 shares during the last quarter. Summit Partners Public Asset Management LLC increased its holdings in Sarepta Therapeutics by 547.9% during the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock valued at $17,250,000 after acquiring an additional 116,800 shares in the last quarter. Finally, Larson Financial Group LLC raised its position in Sarepta Therapeutics by 1,649.8% during the third quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock worth $1,093,000 after acquiring an additional 8,249 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Activity

In related news, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.